Abstract
Dialyzable transfer factor in conjunction with amphotericin B was used in the treatment of a patient with mucocutaneous candidiasis in a longitudinal controlled study over a 2.5-year period. Amphotericin B treatment alone produced a 3-week remission. Transfer factor from Candida-negative donors could not maintain this remission while transfer factor from donors with strong delayed hypersensitivity to Candida antigen could maintain an amphotericin B-induced remission. Further, this clinical response to transfer factor correlated with the appearance of a positive delayed hypersensitivity skin test to Candida antigen and the production of macrophage migration inhibitory factor (MIF) by the patient's lymphocytes when stimulated by this antigen. This observation supports the hypothesis that successful transfer factor therapy is the result of an antigenspecific conversion from the unreactive to the reactive state and not of nonspecific immunostimulation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
